These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 26830074

  • 1. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA, D'Elia JA, Finn P, Lewis EF, Desai AS, Claggett BL, Cooper ME, McGill JB.
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [Abstract] [Full Text] [Related]

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Mar; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Mar; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 4. Type II diabetes mellitus.
    Edelman SV.
    Adv Intern Med; 1998 Mar; 43():449-500. PubMed ID: 9506190
    [Abstract] [Full Text] [Related]

  • 5. Insulin therapy in type 2 diabetes.
    Mudaliar S, Edelman SV.
    Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
    [Abstract] [Full Text] [Related]

  • 6. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C.
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [Abstract] [Full Text] [Related]

  • 7. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
    Scheen AJ.
    Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710
    [Abstract] [Full Text] [Related]

  • 8. Renal function markers and metformin eligibility.
    Tavares Bello C, Castro Fonseca R, Sousa Santos F, Sequeira Duarte J, Azinheira J, Vasconcelos C.
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [Abstract] [Full Text] [Related]

  • 9. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F, Cosmi D.
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, Umpierrez GE.
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [Abstract] [Full Text] [Related]

  • 11. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A.
    Clin Ther; 2007 Feb; 29 Spec No():1236-53. PubMed ID: 18046925
    [Abstract] [Full Text] [Related]

  • 12. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS, Chow CC, Tan KC, Ma RC, Kong AP, Tong PC, Tsang MW, Chan TM, Tang SC, Lee KK, So WY, Tomlinson B.
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [Abstract] [Full Text] [Related]

  • 13. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T, Davies GI, Rice S, Chess J, Stephens JW.
    Diabetes Metab Syndr; 2018 Jun; 12(2):123-127. PubMed ID: 29239764
    [Abstract] [Full Text] [Related]

  • 14. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 15. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO.
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J.
    Am J Cardiol; 2017 Jul 01; 120(1S):S4-S16. PubMed ID: 28606343
    [Abstract] [Full Text] [Related]

  • 17. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, Morano S, Ferrannini E, Pugliese G, Renal Insufficiency and Cardiovascular Events Study Group.
    J Am Geriatr Soc; 2013 Aug 01; 61(8):1253-61. PubMed ID: 23889588
    [Abstract] [Full Text] [Related]

  • 18. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B, Cincotta AH.
    Postgrad Med; 2017 May 01; 129(4):446-455. PubMed ID: 28374645
    [Abstract] [Full Text] [Related]

  • 19. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
    Abbatecola AM, Bo M, Barbagallo M, Incalzi RA, Pilotto A, Bellelli G, Maggi S, Paolisso G, Italian Society of Gerontology and Geriatrics (SIGG), Florence, Italy.
    J Am Med Dir Assoc; 2015 Apr 01; 16(4):349.e7-12. PubMed ID: 25669671
    [Abstract] [Full Text] [Related]

  • 20. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA.
    Postgrad Med; 2013 May 01; 125(3):112-26. PubMed ID: 23748512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.